https://www.selleckchem.com/pr....oducts/pf-06700841.h
57, P=0.0006). On Kaplan-Meier analysis the incidence of MACCE was increased with advancing chronic kidney disease stage based on eGFRcys, but not on eGFRcr, in patients with PAD. Net reclassification index was improved with the addition of eGFRcys to basic predictors. Compared with eGFRcr, eGFRcys may be a more reliable biomarker for MACCE and patient risk stratification. Compared with eGFRcr, eGFRcys may be a more reliable biomarker for MACCE and patient risk stratification. Although longitudinal strain (LS) is known to be reduced
Aimer
Commentaire
Partagez
